Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trialUlrike Leiter, Claus Garbe, Rudolf Stadler et al.|The Lancet Oncology|2016Cited by 704
The LIFE-Adult-Study: objectives and design of a population-based cohort study with 10,000 deeply phenotyped adults in GermanyMarkus Loeffler, Anke Tönjes, Tilman Hensch et al.|BMC Public Health|2015Cited by 374
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel NodeUlrike Leiter, Rudolf Stadler, Cornelia Mauch et al.|Journal of Clinical Oncology|2019Cited by 254
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Jochen Utikal, Elisabeth Livingstone et al.|The Lancet|2020Cited by 242
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trialElisabeth Livingstone, Patrick Terheyden, Lisa Zimmer et al.|The Lancet|2022Cited by 113